The global radiofrequency ablation devices market is expected to register a CAGR of 11.2% during the forecast period of 2018 to 2023.
Radiofrequency ablation (RFA) uses thermal energy to achieve targeted tissue destruction. Within the GI tract, Radiofrequency ablation was primarily studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be one of the common applications. Indications for Radiofrequency ablation within the GI tract continue to progress. It has been used in the treatment of esophageal squamous cell dysplasia, cholangiocarcinoma, radiation proctopathy, gastric antral vascular ectasia (GAVE), and pancreatic neoplasia, among other conditions.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7634
Radiofrequency ablation devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the radiofrequency ablation device in the radiofrequency range of 450 to 500 kHz.
Segmentation
The global radiofrequency ablation devices market is segmented on the basis of type, application, and region.
On the basis of the type, the global radiofrequency ablation devices market is segmented into Unipolar radiofrequency ablation and Bipolar radiofrequency ablation. By application, the global radiofrequency ablation devices market is categorized into Surgical Oncology, Cardiology and Cardiac Rhythm Management, Gynecology, Cosmetology, Pain Management
Key players
Some of the key players in the global radiofrequency ablation devices market are Boston scientific corporation, Medtronic Inc, Stryker, Cosman Medical, Inc., St. Jude Medical, Smith & Nephew, Johnson & Johnson (J&J) Services, LLC, Angiodynamics, RF Medical Co, Ltd, AtriCure, Inc., and others
Regional Market
The Americas dominates the global market for radiofrequency ablation devices owing a growing number of lung cancer cases like, Non-Small Cell Lung Cancer (NSCLC) which is the most common type of lung cancer, accounting for 80-85% of all lung cancer cases. It is generally a slow growing and spreading as compared to small cell lung cancer (SCLC). Small cell lung cancer used to account for 12-13% of lung cancers. However, there has been a shift from NSCLC to SCLC in recent years which has propelled the growth of the radiofrequency ablation devices market.
In 2017, it was estimated that Europe stood second in the global radiofrequency ablation devices market.
Asia-Pacific was the fastest growing region for the global radiofrequency ablation devices market in 2017. Factors such as increasing awareness of the cardiac disease, growing healthcare industries, and the development of various treatment methods for gynecology and cosmetology drives the market in this region.
On the other hand, the Middle East and Africa holds the least share in the global radiofrequency ablation devices market. The presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare for healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/radiofrequency-ablation-devices-market-7634
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Comments